{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T15:29:37Z","timestamp":1791905377429,"version":"4.3.4"},"reference-count":94,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2005,7,12]],"date-time":"2005-07-12T00:00:00Z","timestamp":1121126400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2005,11]]},"DOI":"10.1007\/s00520-005-0849-9","type":"journal-article","created":{"date-parts":[[2005,7,11]],"date-time":"2005-07-11T09:56:51Z","timestamp":1121075811000},"page":"878-887","source":"Crossref","is-referenced-by-count":42,"title":["Buprenorphine in cancer pain"],"prefix":"10.1007","volume":"13","author":[{"given":"Mellar P.","family":"Davis","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2005,7,12]]},"reference":[{"issue":"7","key":"849_CR1","doi-asserted-by":"crossref","first-page":"717","DOI":"10.2174\/1381612043453027","volume":"10","author":"JW Lewis","year":"2004","unstructured":"Lewis JW, Husbands SM (2004) The orvinols and related opioids\u2014high affinity ligands with diverse efficacy profiles. Curr Pharm Des 10(7):717\u2013732","journal-title":"Curr Pharm Des"},{"issue":"Suppl","key":"849_CR2","first-page":"3","volume":"133","author":"A Cowan","year":"2003","unstructured":"Cowan A (2003) Buprenorphine: new pharmacological aspects. Int J Clin Pract 133(Suppl):3\u20138","journal-title":"Int J Clin Pract"},{"issue":"3","key":"849_CR3","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1016\/0014-2999(88)90543-2","volume":"151","author":"JD Leander","year":"1988","unstructured":"Leander JD (1988) Buprenorphine is a potent kappa-opioid receptor antagonist in pigeons and mice. Eur J Pharmacol 151(3):457\u2013461","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"849_CR4","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/0028-3908(87)90112-2","volume":"26","author":"JD Leander","year":"1987","unstructured":"Leander JD (1987) Buprenorphine has potent kappa opioid receptor antagonist activity. Neuropharmacology 26(9):1445\u20131447","journal-title":"Neuropharmacology"},{"key":"849_CR5","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/S0006-8993(96)01069-4","volume":"744","author":"CG Pick","year":"1997","unstructured":"Pick CG, Peter Y, Schreiber S et al (1997) Pharmacological characterization of buprenorphine, a mixed agonist\u2013antagonist with k3 analgesia. Brain Res 744:41\u201346","journal-title":"Brain Res"},{"issue":"22","key":"849_CR6","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1016\/S0024-3205(97)00170-7","volume":"60","author":"J Kamei","year":"1997","unstructured":"Kamei J, Sodeyama M, Tsuda M et al (1997) Antinociceptive effect of buprenorphine in mu1-opioid receptor deficient CXBK mice. Life Sci 60(22):333\u2013337","journal-title":"Life Sci"},{"issue":"1","key":"849_CR7","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/0014-2999(88)90149-5","volume":"156","author":"SS Negus","year":"1988","unstructured":"Negus SS, Kykstra LA (1988) Kappa antagonist properties of buprenorphine in the shock titration procedure. Eur J Pharmacol 156(1):77\u201386","journal-title":"Eur J Pharmacol"},{"issue":"9","key":"849_CR8","first-page":"1956","volume":"29","author":"S Ide","year":"2004","unstructured":"Ide S, Minami M, Satoh M et al (2004) Buprenorphine antinociception is abolished, but naloxone-sensitive reward is retained, in mu-opioid receptor knockout mice. Neuropsychopharmacology 29(9):1956\u20131963","journal-title":"Neuropsychopharmacology"},{"issue":"2","key":"849_CR9","doi-asserted-by":"crossref","first-page":"652","DOI":"10.1124\/jpet.104.071423","volume":"311","author":"MD Recker","year":"2004","unstructured":"Recker MD, Higgins GA (2004) The opioid receptor like-1 receptor agonists Ro 64\u20136198 (1S, 3aS-8-2,3,3a,4,5,6-hexahydro-1H-phenalen-1-yl-1-phenyl-1,3,8-triaza-spiro [4.5] decan-4-one) produces a discriminative stimulus in rats distinct from that of a mu, kappa, and delta opioid receptor agonist cue. J Pharmacol Exp Ther 311(2):652\u2013658. DOI 10.1124\/jpet.104.071423","journal-title":"J Pharmacol Exp Ther"},{"issue":"Suppl","key":"849_CR10","doi-asserted-by":"crossref","first-page":"315S","DOI":"10.1111\/j.1365-2125.1979.tb04706.x","volume":"7","author":"DS Robbie","year":"1979","unstructured":"Robbie DS (1979) Trial of sublingual buprenorphine in cancer pain. Clin Pharmacol 7(Suppl):315S\u2013317S","journal-title":"Clin Pharmacol"},{"issue":"7","key":"849_CR11","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/0885-3924(91)90041-2","volume":"6","author":"E Campora","year":"1991","unstructured":"Campora E, Merlini L, Pace M et al (1991) The incidence of narcotic-induced emesis. J Pain Symptom Manage 6(7):428\u2013430","journal-title":"J Pain Symptom Manage"},{"issue":"7","key":"849_CR12","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/0885-3924(91)90040-B","volume":"6","author":"F Conno De","year":"1991","unstructured":"De Conno F, Ripamonti C, Sbanotto A et al (1991) A clinical study on the use of codeine, oxycodone, dextropropoxyphene, buprenorphine, and pentazocine in cancer pain. J Pain Symptom Manage 6(7):423\u2013427","journal-title":"J Pain Symptom Manage"},{"issue":"4","key":"849_CR13","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1365-2125.1982.tb01409.x","volume":"13","author":"M Kjaer","year":"1982","unstructured":"Kjaer M, Henriksen H, Knudsen J (1982) A comparative study of intramuscular buprenorphine and morphine in the treatment of chronic pain of malignant origin. Br J Clin Pharmacol 13(4):487\u2013492","journal-title":"Br J Clin Pharmacol"},{"issue":"4","key":"849_CR14","first-page":"587","volume":"33","author":"V Ventafridda","year":"1983","unstructured":"Ventafridda V, De Conno F, Guarise G et al (1983) Chronic analgesic study on buprenorphine action in cancer pain. Comparison with pentazocine. Arzneimittelforschung 33(4):587\u2013590","journal-title":"Arzneimittelforschung"},{"issue":"12","key":"849_CR15","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1055\/s-2008-1068844","volume":"110","author":"M Zenz","year":"1985","unstructured":"Zenz M, Piepenbrock S, Tryba M et al (1985) Long-term therapy of cancer pain. A controlled study on buprenorphine. Dtsch Med Wochenschr 110(12):448\u2013453","journal-title":"Dtsch Med Wochenschr"},{"issue":"23","key":"849_CR16","doi-asserted-by":"crossref","first-page":"2629","DOI":"10.2165\/00003495-200464230-00002","volume":"64","author":"TL Skaer","year":"2004","unstructured":"Skaer TL (2004) Practice guidelines for transdermal opioids in malignant pain. Drugs 64(23):2629\u20132638","journal-title":"Drugs"},{"issue":"19","key":"849_CR17","doi-asserted-by":"crossref","first-page":"1999","DOI":"10.2165\/00003495-200363190-00003","volume":"63","author":"HC Evans","year":"2003","unstructured":"Evans HC, Easthope SE (2003) Transdermal buprenorphine. Drugs 63(19):1999\u20132010","journal-title":"Drugs"},{"issue":"14","key":"849_CR18","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1016\/S0024-3205(00)00436-7","volume":"66","author":"RB Ibrahim","year":"2000","unstructured":"Ibrahim RB, Wilson JG, Thorsby ME et al (2000) Effect of buprenorphine on CYP3A activity in rat and human liver. Life Sci 66(14):1293\u20131298","journal-title":"Life Sci"},{"issue":"5","key":"849_CR19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.annemergmed.2003.11.006","volume":"43","author":"KA Sporer","year":"2004","unstructured":"Sporer KA (2004) Buprenorphine: a primer for emergency physicians. Ann Emerg Med 43(5):1\u20137","journal-title":"Ann Emerg Med"},{"issue":"11","key":"849_CR20","doi-asserted-by":"crossref","first-page":"2000","DOI":"10.1038\/sj.npp.1300251","volume":"28","author":"MK Greenwald","year":"2003","unstructured":"Greenwald MK, Johanson CE, Moody DE et al (2003) Effects of buprenorphine maintenance dose on mu-opioid receptor availability, plasma concentrations, and antagonist blockade in heroin-dependent volunteers. Neuropsychopharmacology 28(11):2000\u20132009","journal-title":"Neuropsychopharmacology"},{"issue":"1\u20132","key":"849_CR21","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.devbrainres.2004.05.002","volume":"151","author":"Y Hou","year":"2004","unstructured":"Hou Y, Tan Y, Belcheva MM et al (2004) Differential effects of gestational buprenorphine, naloxone, and methadone on mesolimbic mu opioid and ORL1 receptor G protein coupling. Brain Res Dev Brain Res 151(1\u20132):149\u2013157","journal-title":"Brain Res Dev Brain Res"},{"issue":"32","key":"849_CR22","doi-asserted-by":"crossref","first-page":"10331","DOI":"10.1523\/JNEUROSCI.23-32-10331.2003","volume":"23","author":"K Lutfy","year":"2003","unstructured":"Lutfy K, Eitan S, Bryant CD, Yang YC, Saliminejad N, Walwyn W (2003) Buprenorphine-induced antinociception is mediated by mu-opioid receptors and compromised by concomitant activation of opioid receptor-like receptors. J Neurosci 23(32):10331\u201310337","journal-title":"J Neurosci"},{"issue":"7","key":"849_CR23","doi-asserted-by":"crossref","first-page":"557","DOI":"10.1097\/00008877-200211000-00005","volume":"13","author":"SS Negus","year":"2002","unstructured":"Negus SS, Bidlac JM, Mello NK et al (2002) Delta opioid antagonist effects of buprenorphine in rhesus monkeys. Behav Pharmacol 13(7):557\u2013570","journal-title":"Behav Pharmacol"},{"issue":"3","key":"849_CR24","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1016\/j.jpainsymman.2004.07.005","volume":"29","author":"RE Johnson","year":"2005","unstructured":"Johnson RE, Fudala PJ, Payne R (2005) Buprenorphine: considerations for pain management. J Pain Symptom Manage 29(3):297","journal-title":"J Pain Symptom Manage"},{"issue":"5","key":"849_CR25","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/j.1875-9114.1986.tb03481.x","volume":"6","author":"SL Wallenstein","year":"1986","unstructured":"Wallenstein SL, Kaiko RJ, Rogers AG et al (1986) Crossover trials in clinical analgesic assays: studies of buprenorphine and morphine. Pharmacotherapy 6(5):228\u2013235","journal-title":"Pharmacotherapy"},{"key":"849_CR26","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/j.ejphar.2004.03.041","volume":"492","author":"A Bulka","year":"2004","unstructured":"Bulka A, Kouya PF, Bottiger Y et al (2004) Comparison of the antinociceptive effects of morphine, methadone, buprenorphine and codeine in two substrains of Sprague\u2013Dawley rats. Eur J Pharmacol 492:27\u201334","journal-title":"Eur J Pharmacol"},{"issue":"1","key":"849_CR27","first-page":"368","volume":"264","author":"JM Thomas","year":"1993","unstructured":"Thomas JM, Hoffman BB (1993) Buprenorphine prevents and reverses the expression of chronic etorphine-induced sensitization of adenylyl cyclase in SK-N-SH human neuroblastoma cells. J Pharamacol Exp Ther 264(1):368\u2013374","journal-title":"J Pharamacol Exp Ther"},{"issue":"5","key":"849_CR28","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1093\/bja\/58.5.508","volume":"58","author":"MV Shah","year":"1986","unstructured":"Shah MV, Jones DI, Rosen M (1986) \u201cPatient demand\u201d postoperative analgesia with buprenorphine. Comparison between sublingual and i.m. administration. Br J Anaesth 58(5):508\u2013511","journal-title":"Br J Anaesth"},{"issue":"1\u20133","key":"849_CR29","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.ejphar.2004.11.052","volume":"507","author":"T Christoph","year":"2005","unstructured":"Christoph T, Kogel B, Schiene K, Meen M, De Vry J, Friderichs E (2005) Broad analgesic profile of buprenorphine in rodent models of acute and chronic pain. Eur J Pharmacol 507(1\u20133):87\u201398","journal-title":"Eur J Pharmacol"},{"key":"849_CR30","doi-asserted-by":"crossref","first-page":"55","DOI":"10.1016\/S0376-8716(99)00012-5","volume":"56","author":"KJ Schuh","year":"1999","unstructured":"Schuh KJ, Johanson CE (1999) Pharmacokinetic comparison of the buprenorphine sublingual liquid and tablet. Drug Alcohol Depend 56:55\u201360","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"849_CR31","first-page":"202","volume":"30","author":"C Tantucci","year":"1992","unstructured":"Tantucci C, Paoletti F, Bruni B et al (1992) Acute respiratory effects of sublingual buprenorphine: comparison with intramuscular morphine. Int J Clin Pharmacol Ther Toxicol 30(6):202\u2013207","journal-title":"Int J Clin Pharmacol Ther Toxicol"},{"issue":"6","key":"849_CR32","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1093\/bja\/aei145","volume":"94","author":"A Dahan","year":"2005","unstructured":"Dahan A, Yassen A, Bijl H, Romberg R, Sarton E, Teppema L (2005) Comparison of the respiratory effects of intravenous buprenorphine and fentanyl in humans and rats. Br J Anaesth 94(6):825\u2013834. DOI 10.1093\/bja\/aeil45","journal-title":"Br J Anaesth"},{"issue":"2","key":"849_CR33","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/S1353-1131(03)00039-7","volume":"10","author":"F Clarot","year":"2003","unstructured":"Clarot F, Pierre GJ, Vaz E et al (2003) Tramadol-benzodiazepines and buprenorphine-benzodiazepines two potentially fatal cocktails. J Clin Forensic Med 10(2):125\u2013126","journal-title":"J Clin Forensic Med"},{"issue":"7","key":"849_CR34","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1016\/S0009-9120(02)00304-1","volume":"35","author":"P Kintz","year":"2002","unstructured":"Kintz P (2002) A new series of 13 buprenorphine-related deaths. Clin Biochem 35(7):513\u2013516","journal-title":"Clin Biochem"},{"issue":"1","key":"849_CR35","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1520\/JFS14667J","volume":"45","author":"JM Gaulier","year":"2000","unstructured":"Gaulier JM, Marquet P, Lacassie E, Dupuy JL, Lachatre G (2000) Fatal intoxication following self-administration of a massive dose of buprenorphine. J Forensic Sci 45(1):226\u2013228","journal-title":"J Forensic Sci"},{"issue":"3","key":"849_CR36","first-page":"35","volume":"18","author":"C Stock","year":"2004","unstructured":"Stock C, Shum JH (2004) Buprenorphine: a new pharmacotherapy for opioid addictions treatment. J Pain Palliat Care Pharmacother 18(3):35\u201354","journal-title":"J Pain Palliat Care Pharmacother"},{"key":"849_CR37","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.017","volume":"75","author":"G Gerra","year":"2004","unstructured":"Gerra G, Borella F, Zaimovic A et al (2004) Buprenorphine versus methadone for opioid dependence: predictor variables for treatment outcome. Drug Alcohol Depend 75:37\u201345","journal-title":"Drug Alcohol Depend"},{"key":"849_CR38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.drugalcdep.2004.07.008","volume":"77","author":"MR Oreskovich","year":"2005","unstructured":"Oreskovich MR, Saxon AJ, Ellis MLK et al (2005) A double-blind, double-dummy, randomized, prospective pilot study of the partial Mu opiate agonist, buprenorphine, for acute detoxification from heroin. Drug Alcohol Depend 77:71\u201379","journal-title":"Drug Alcohol Depend"},{"key":"849_CR39","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1002\/jps.2600830204","volume":"83","author":"SD Roy","year":"1994","unstructured":"Roy SD, Roos E, Sharma K (1994) Transdermal delivery of buprenorphine through cadaver skin. J Pharm Sci 83:126\u2013130","journal-title":"J Pharm Sci"},{"key":"849_CR40","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0168-8278(00)00050-7","volume":"34","author":"A Berson","year":"2001","unstructured":"Berson A, Fau D, Fornacciari R et al (2001) Mechanisms for experimental buprenorphine hepatotoxicity: major role of mitochondrial dysfunction versus metabolic activation. J Hepatol 34:261\u2013269","journal-title":"J Hepatol"},{"key":"849_CR41","first-page":"P2","volume":"69","author":"KC Lasseter","year":"2001","unstructured":"Lasseter KC, Venitz J, Eltahtawy A, Miotto J, Munera C (2001) Systemic pharmacokinetic (PK) study of buprenorphine (B) in mild to moderate chronic hepatic impairment (CHI). Clin Pharmacol Ther 69:P2 Abstract PI-4","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"849_CR42","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1038\/sj.bjp.0703321","volume":"130","author":"S Sbrenna","year":"2000","unstructured":"Sbrenna S, Marti M, Morari M, Calo\u2019 G et al (2000) Modulation of 5-hydroxytryptamine efflux from rat cortical synaptosomes by opioids and nociceptin. Br J Pharmacol 130(2):425\u2013433","journal-title":"Br J Pharmacol"},{"key":"849_CR43","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1016\/j.eurpsy.2004.09.002","volume":"19","author":"AJ Dean","year":"2004","unstructured":"Dean AJ, Bell J, Christie MJ et al (2004) Depressive symptoms during buprenorphine vs. methadone maintenance: findings from a randomised, controlled trial in opioid dependence. Eur Psychiatr 19:510\u2013513","journal-title":"Eur Psychiatr"},{"issue":"2","key":"849_CR44","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/S0378-5173(01)00591-9","volume":"217","author":"K Lindhardt","year":"2001","unstructured":"Lindhardt K, Bagger M, Andreasen KH, Bechgaard E (2001) Intranasal bioavailability of buprenorphine in rabbit correlated to sheep and man. Int J Pharm 217(2):121\u2013126","journal-title":"Int J Pharm"},{"key":"849_CR45","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/S0376-8716(03)00188-1","volume":"72","author":"SD McAleer","year":"2003","unstructured":"McAleer SD, Mills RJ, Polack T et al (2003) Pharmacokinetics of high-dose buprenorphine following single administration of sublingual tablet formulations in opioid naive healthy male volunteers under a naltrexone block. Drug Alcohol Depend 72:75\u201383","journal-title":"Drug Alcohol Depend"},{"key":"849_CR46","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.drugalcdep.2003.11.008","volume":"74","author":"EC Strain","year":"2004","unstructured":"Strain EC, Mood DE, Stoller KB et al (2004) Relative bioavailability of different buprenorphine formulations under chronic dosing conditions. Drug Alcohol Depend 74:37\u201343","journal-title":"Drug Alcohol Depend"},{"issue":"6","key":"849_CR47","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1177\/00912709922008236","volume":"39","author":"RP Nath","year":"1999","unstructured":"Nath RP, Upton RA, Everhart ET et al (1999) Buprenorphine pharmacokinetics: relative bioavailability of sublingual tablet and liquid formulations. J Clin Pharmacol 39(6):619\u2013623","journal-title":"J Clin Pharmacol"},{"issue":"5","key":"849_CR48","first-page":"191","volume":"101","author":"M Zenz","year":"1983","unstructured":"Zenz M, Piepenbrock S, Tryba M et al (1983) Sublingual buprenorphine tablets: initial clinical experiences in long-term therapy of cancer pain. Fortschr Med 101(5):191\u2013194","journal-title":"Fortschr Med"},{"issue":"5","key":"849_CR49","doi-asserted-by":"crossref","first-page":"329","DOI":"10.2165\/00003088-200443050-00005","volume":"43","author":"DS Harris","year":"2004","unstructured":"Harris DS, Mendelson JE, Lin ET et al (2004) Pharmacokinetics and subjective effects of sublingual buprenorphine, alone or in combination with naloxone. Clin Pharmacokinet 43(5):329\u2013340","journal-title":"Clin Pharmacokinet"},{"issue":"5","key":"849_CR50","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1124\/dmd.105.003681","volume":"33","author":"N Picard","year":"2005","unstructured":"Picard N, Cresteil T, Djebli N, Marquet P (2005) In vitro metabolism study of buprenorphine: evidence for new metabolic pathways. Drug Metab Dispos 33(5):689\u2013695","journal-title":"Drug Metab Dispos"},{"issue":"14","key":"849_CR51","doi-asserted-by":"crossref","first-page":"983","DOI":"10.2165\/00003088-200443140-00003","volume":"43","author":"J Lotsch","year":"2004","unstructured":"Lotsch J, Skarke C, Liefhold J et al (2004) Genetic predictors of the clinical response to opioid analgesics. Clin Pharmaocokinet 43(14):983\u20131013","journal-title":"Clin Pharmaocokinet"},{"issue":"6","key":"849_CR52","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1124\/dmd.31.6.762","volume":"31","author":"MG Soars","year":"2003","unstructured":"Soars MG, Ring BJ, Wrighton SA (2003) The effect of incubation conditions on the enzyme kinetics of UDP-glucuronosyltransferases. Drug Metab Dispos 31(6):762\u2013767","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"849_CR53","first-page":"507","volume":"26","author":"MD Green","year":"1998","unstructured":"Green MD, King CD, Mojarrabi B et al (1998) Glucuronidation of amines and other xenobiotics catalyzed by expressed human UDP-glucuronosyltransferase 1A3. Drug Metab Dispos 26(6):507\u2013512","journal-title":"Drug Metab Dispos"},{"issue":"11","key":"849_CR54","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1124\/dmd.104.000794","volume":"32","author":"JA Williams","year":"2004","unstructured":"Williams JA, Hyland R, Jones BC et al (2004) Drug\u2013drug interactions for UDP-glucuronosyltransferase substrates: a pharmacokinetic explanation for typically observed low exposure (AUCi\/AUC) ratios. Drug Metab Dispos 32(11):1201\u20131208","journal-title":"Drug Metab Dispos"},{"issue":"8","key":"849_CR55","first-page":"818","volume":"26","author":"K Kobayashi","year":"1998","unstructured":"Kobayashi K, Yamamoto T, Chiba T et al (1998) Human buprenorphine N-dealkylation is catalyzed by cytochrome P450 3A4. Drug Metab Dispos 26(8):818\u2013821","journal-title":"Drug Metab Dispos"},{"issue":"5","key":"849_CR56","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1248\/bpb.25.682","volume":"25","author":"K Umehara","year":"2002","unstructured":"Umehara K, Shimokawa Y, Miyamoto G (2002) Inhibition of human drug metabolizing cytochrome P450 by buprenorphine. Biol Pharm Bull 25(5):682\u2013685","journal-title":"Biol Pharm Bull"},{"issue":"6","key":"849_CR57","doi-asserted-by":"crossref","first-page":"768","DOI":"10.1124\/dmd.31.6.768","volume":"31","author":"W Zhang","year":"2003","unstructured":"Zhang W, Ramamoorthy Y, Tyndale RF et al (2003) Interaction of buprenorphine and its metabolite norbuprenorpine with cytochromes P450 in vitro. Drug Metab Dispos 31(6):768\u2013772","journal-title":"Drug Metab Dispos"},{"issue":"2","key":"849_CR58","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1248\/bpb.28.212","volume":"28","author":"S Umeda","year":"2005","unstructured":"Umeda S, Harakawa N, Yamamoto M, Ueno K (2005) Effect of nonspecific binding to microsomes and metabolic elimination of buprenorphine on the inhibition of cytochrome P4502D6. Biol Pharm Bull 28(2):212\u2013216","journal-title":"Biol Pharm Bull"},{"issue":"1","key":"849_CR59","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.drugalcdep.2004.08.027","volume":"78","author":"HE Jones","year":"2005","unstructured":"Jones HE, Johnson RE, Jasinki DR, Milio L (2005) Randomized controlled study transitioning opioid-dependent pregnant women from short-acting morphine to buprenorphine or methadone. Drug Alcohol Depend 78(1):33\u201338","journal-title":"Drug Alcohol Depend"},{"key":"849_CR60","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/0304-3959(87)90042-X","volume":"29","author":"V Pasqualucci","year":"1987","unstructured":"Pasqualucci V, Tantucci C, Paoletti F et al (1987) Buprenorphine vs. morphine via the epidural route: a controlled comparative clinical study of respiratory effect and analgesic activity. Pain 29:273\u2013286","journal-title":"Pain"},{"key":"849_CR61","first-page":"9","volume":"133","author":"K Budd","year":"2003","unstructured":"Budd K (2003) Buprenorphine and the transdermal system: the ideal match in pain management. Int J Clin Pract (Suppl) 133:9\u201314","journal-title":"Int J Clin Pract (Suppl)"},{"issue":"1","key":"849_CR62","first-page":"73","volume":"26","author":"BL Coffman","year":"1998","unstructured":"Coffman BL, King CD, Rios GR et al (1998) The glucuronidation of opioids, other xenobiotics, and androgen by human UGT2B7Y (268) and UGT2B7H (268). Drug Metab Dispos 26(1):73\u201377","journal-title":"Drug Metab Dispos"},{"issue":"1","key":"849_CR63","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/S0149-2918(03)90019-1","volume":"25","author":"R Sittl","year":"2003","unstructured":"Sittl R, Griessinger N, Likar R (2003) Analgesic efficacy and tolerability of transdermal buprenorphine in patients with inadequately controlled chronic pain related to cancer and other disorders: a multicenter, randomized, double-blind, placebo-controlled trial. Clin Ther 25(1):150\u2013168","journal-title":"Clin Ther"},{"issue":"11","key":"849_CR64","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1016\/j.clinthera.2004.11.008","volume":"26","author":"J Sorge","year":"2004","unstructured":"Sorge J, Sittl R (2004) Transdermal buprenorphine in the treatment of chronic pain: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. Clin Ther 26(11):1808\u20131820","journal-title":"Clin Ther"},{"issue":"13\u201314","key":"849_CR65","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1046\/j.1563-258X.2003.02120.x","volume":"153","author":"R Likar","year":"2003","unstructured":"Likar R, Griessinger N, Sadjak A et al (2003) Transdermal buprenorphine for treatment of chronic tumor and non-tumor pain. Wien Med Wochenschr 153(13\u201314):317\u2013322","journal-title":"Wien Med Wochenschr"},{"issue":"5","key":"849_CR66","first-page":"577","volume":"12","author":"EJ Cone","year":"1984","unstructured":"Cone EJ, Gorodetzky CW, Yousefnejad D et al (1984) The metabolism and excretion of buprenorphine in humans. Drug Metab Dispos 12(5):577\u2013581","journal-title":"Drug Metab Dispos"},{"issue":"6","key":"849_CR67","first-page":"379","volume":"57","author":"R Manzi","year":"1991","unstructured":"Manzi R, Rizzi M, D\u2019Elia F et al (1991) Use of buprenorphine after right hepatectomy. Minerva Anestesiol 57(6):379\u2013382","journal-title":"Minerva Anestesiol"},{"key":"849_CR68","first-page":"19","volume":"133","author":"L Radbruch","year":"2003","unstructured":"Radbruch L (2003) Buprenorphine TDS: use in daily practice, benefits for patients. Int J Clin Pract (Suppl) 133:19\u201322","journal-title":"Int J Clin Pract (Suppl)"},{"key":"849_CR69","first-page":"15","volume":"133","author":"L Radbruch","year":"2003","unstructured":"Radbruch L, Vielvoye-Kerkmeer A (2003) Buprenorphine TDS: the clinical development rationale and results. Int J Clin Pract (Suppl) 133:15\u201318","journal-title":"Int J Clin Pract (Suppl)"},{"issue":"2","key":"849_CR70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1097\/00002508-198906000-00004","volume":"5","author":"J Noda","year":"1989","unstructured":"Noda J, Umeda S, Arai T et al (1989) Continuous subcutaneous infusion of buprenorphine for cancer pain control. Clin J Pain 5(2):147\u2013152","journal-title":"Clin J Pain"},{"issue":"2","key":"849_CR71","first-page":"69","volume":"38","author":"Y Hashimoto","year":"1991","unstructured":"Hashimoto Y, Utsumi T, Tanioka H et al (1991) Epidural buprenorphine or morphine for the relief of head and neck cancer pain. Anesth Prog 38(2):69\u201371","journal-title":"Anesth Prog"},{"issue":"1\u20132","key":"849_CR72","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1007\/BF01402188","volume":"102","author":"N Francaviglia","year":"1990","unstructured":"Francaviglia N, Silvestro C, Carta F et al (1990) Subarachnoid buprenorphine administered by implantable micropumps. Acta Neurochir (Wien) 102(1\u20132):62\u201368","journal-title":"Acta Neurochir (Wien)"},{"issue":"11\u201312","key":"849_CR73","first-page":"609","volume":"51","author":"S Lari","year":"1995","unstructured":"Lari S, Fabbri G, Mattioli R et al (1995) Epidural buprenorphine versus morphine in bone cancer pain. Minerva Anestesiol 51(11\u201312):609\u2013614","journal-title":"Minerva Anestesiol"},{"key":"849_CR74","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1016\/j.phrs.2004.05.002","volume":"50","author":"A Ferrari","year":"2004","unstructured":"Ferrari A, Coccia CPR, Bertolini A et al (2004) Methadone-metabolism, pharmacokinetics and interactions. Pharmacol Res 50:551\u2013559","journal-title":"Pharmacol Res"},{"issue":"22","key":"849_CR75","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1136\/vr.152.22.675","volume":"152","author":"SA Robertson","year":"2003","unstructured":"Robertson SA, Taylor PM, Sear JW (2003) Systemic uptake of buprenorphine by cats after oral mucosal administration. Vet Rec 152(22):675\u2013678","journal-title":"Vet Rec"},{"key":"849_CR76","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1111\/j.1472-8206.1998.tb00941.x","volume":"12","author":"C Iribarne","year":"1998","unstructured":"Iribarne C, Picart D, Dreano Y et al (1998) In vitro interactions between fluoxetine or fluvoxamine and methadone or buprenorphine. Fundam Clin Pharmacol 12:194\u2013199","journal-title":"Fundam Clin Pharmacol"},{"issue":"6","key":"849_CR77","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1093\/jat\/28.6.464","volume":"28","author":"C Giroud","year":"2004","unstructured":"Giroud C, Michaud K, Sporkert F et al (2004) A fatal overdose of cocaine associated with coingestion of marijuana, buprenorphine, and fluoxetine. Body fluid and tissue distribution of cocaine and its metabolites determined by hydrophilic interaction chromatography\u2013mass spectrometry (HILIC-MS). J Anal Toxicol 28(6):464\u2013474","journal-title":"J Anal Toxicol"},{"issue":"8","key":"849_CR78","doi-asserted-by":"crossref","first-page":"978","DOI":"10.1111\/j.1360-0443.2004.00790.x","volume":"99","author":"S Pirnay","year":"2004","unstructured":"Pirnay S, Borron SW, Giudicelli CP et al (2004) A critical review of the causes of death among post-mortem toxicological investigations: analysis of 34 buprenorphine-associated and 35 methadone-associated deaths. Addiction 99(8):978\u2013988","journal-title":"Addiction"},{"issue":"6","key":"849_CR79","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1023\/A:1008771621812","volume":"21","author":"A Jappinen","year":"1999","unstructured":"Jappinen A, Kokki H, Naaranlahti TJ et al (1999) Stability of buprenorphine, haloperidol and glycopyrrolate mixture in a 0.9% sodium chloride solution. Pharm World Sci 21(6):272\u2013274","journal-title":"Pharm World Sci"},{"issue":"3","key":"849_CR80","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1080\/0959523031000154508","volume":"22","author":"GF Feeney","year":"2003","unstructured":"Feeney GF, Fairweather P (2003) Groin tissue necrosis requiring skin graft following parenteral abuse of buprenorphine tablets. Drug Alcohol Rev 22(3):359\u2013361","journal-title":"Drug Alcohol Rev"},{"issue":"1","key":"849_CR81","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1210\/jc.2004-0929","volume":"90","author":"N Bliesener","year":"2005","unstructured":"Bliesener N, Albrecht S, Schwager A et al (2005) Plasma testosterone and sexual function in men on buprenorphine maintenance for opioid dependence. J Clin Endocrinol Metab 90(1):203\u2013206","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"849_CR82","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1016\/S0885-3924(03)00069-1","volume":"25","author":"F Conno De","year":"2003","unstructured":"De Conno F, Panzeri C, Brunelli C et al (2003) Palliative care in a National Cancer Center: results in 1987 vs. 1993 vs. 2000. J Pain Symptom Manage 25(6):499\u2013511","journal-title":"J Pain Symptom Manage"},{"issue":"10","key":"849_CR83","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1111\/j.1742-1241.1979.tb07675.x","volume":"33","author":"MJ Ostrowski","year":"1979","unstructured":"Ostrowski MJ, Jacson AW (1979) Intra-muscular buprenorphine\u2014clinical experience in its use for relieving pain due to malignant disease. Br J Clin Pract 33(10):286, 293","journal-title":"Br J Clin Pract"},{"issue":"2","key":"849_CR84","first-page":"250","volume":"9","author":"T Taguchi","year":"1982","unstructured":"Taguchi T (1982) Effect of a long-acting analgesic, buprenorphine on cancer pain a single-blind crossover comparison with pentazocine. Gan To Kagaku Ryoho 9(2):250\u2013257","journal-title":"Gan To Kagaku Ryoho"},{"issue":"3\u20134","key":"849_CR85","first-page":"93","volume":"77","author":"D Dini","year":"1986","unstructured":"Dini D, Fassio T, Gottlieb A et al (1986) Controlled study of the analgesic effect and tolerability of buprenorphine in cancer patients. Minerva Med 77(3\u20134):93\u2013104","journal-title":"Minerva Med"},{"issue":"15","key":"849_CR86","first-page":"1177","volume":"78","author":"F Conno De","year":"1987","unstructured":"De Conno F, Ripamonti C, Tamburini M et al (1987) Buprenorphine in cancer pain: cross comparison with pentazocine. Minerva Med 78(15):1177\u20131181","journal-title":"Minerva Med"},{"issue":"3","key":"849_CR87","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1177\/082585979300900302","volume":"9","author":"F Conno De","year":"1993","unstructured":"De Conno F, Ripamonti C, Sbanotto A et al (1993) A clinical note on sublingual buprenorphine. J Palliat Care 9(3):44\u201346","journal-title":"J Palliat Care"},{"issue":"4\u20135","key":"849_CR88","first-page":"109","volume":"16","author":"F Brema","year":"1996","unstructured":"Brema F, Pastorino G, Martini MD et al (1996) Oral tramadol and buprenorphine in tumour pain. An Italian multicentre trial. Int J Clin Pharmacol Res 16(4\u20135):109\u2013116","journal-title":"Int J Clin Pharmacol Res"},{"issue":"Suppl 2","key":"849_CR89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.2165\/00003495-199700532-00009","volume":"53","author":"AV Bono","year":"1997","unstructured":"Bono AV, Cuffari S (1997) Effectiveness and tolerance of tramadol in cancer pain. A comparative study with respect to buprenorphine. Drugs 53(Suppl 2):40\u201349","journal-title":"Drugs"},{"key":"849_CR90","doi-asserted-by":"crossref","first-page":"882","DOI":"10.1007\/s00520-004-0695-1","volume":"12","author":"P Schriek","year":"2004","unstructured":"Schriek P (2004) Treatment of cancer-related pain with transdermal buprenorphine: a report of three cases. Support Care Cancer 12:882\u2013884","journal-title":"Support Care Cancer"},{"key":"849_CR91","first-page":"2866","volume-title":"Physicians\u2019 desk reference","author":"PDR","year":"2004","unstructured":"PDR (2004) Physicians\u2019 desk reference, 58th edn. Thompson, Montvale, NJ, pp 2866\u20132869","edition":"58"},{"key":"849_CR92","first-page":"1026","volume":"41","author":"B Reidenberg","year":"2001","unstructured":"Reidenberg B, El-Tahtawy A, Munera C et al (2001) Absolute bioavailability of a novel buprenorphine transdermal system (BTDS) applied for seven days. J Clin Pharmacol 41:1026","journal-title":"J Clin Pharmacol"},{"key":"849_CR93","first-page":"1027","volume":"41","author":"B Reidenberg","year":"2001","unstructured":"Reidenberg B, El-Tahtaway A, Munera C et al (2001) Daily pharmacokinetic performance of a buprenorphine transdermal system (BTDS) for up to seven days. J Clin Pharmacol 41:1027","journal-title":"J Clin Pharmacol"},{"issue":"2","key":"849_CR94","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.clinthera.2005.02.012","volume":"27","author":"R Sittl","year":"2005","unstructured":"Sittl R, Likar R, Nautrup BP (2005) Equipotent doses of transdermal fentanyl and transdermal buprenorphine in patients with cancer and noncancer pain: results of a retrospective cohort study. Clin Ther 27(2):225\u2013237","journal-title":"Clin Ther"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-005-0849-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-005-0849-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-005-0849-9","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,1,27]],"date-time":"2024-01-27T20:32:43Z","timestamp":1706387563000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-005-0849-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2005,7,12]]},"references-count":94,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2005,11]]}},"alternative-id":["849"],"URL":"https:\/\/doi.org\/10.1007\/s00520-005-0849-9","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2005,7,12]]}}}